Skip to main content
Premium Trial:

Request an Annual Quote

Rudy Potenzone, Per Artur Peterson, Robert Kolodner

Rudy Potenzone has joined Microsoft as worldwide industry technology strategist for pharmaceuticals. Potenzone was most recently vice president for enterprise solutions at CambridgeSoft. Prior to that, he served as vice president of product management at Ingenuity, president of Lion Biosciences US, senior vice president of research and development at MDL, and director of new product development and research for the American Chemical Society.

Entelos has appointed Per Artur Peterson to its board as a non-executive director. Peterson recently retired as chairman of research and development at Johnson & Johnson, where he was responsible for J&J’s corporate office of science and technology, the enterprise-wide R&D council, and J& J’s cell therapy research activities.
Peterson joined J&J’s R.W. Johnson Pharmaceutical Research Institute in 1994 as vice president of drug discovery. Prior to that, he spent eight years at Scripps Research Institute, where he led the division of molecular immunogenetics before being appointed chairman of the department of immunology in 1987. He also served as director of the Wallenberg Laboratory and as professor of cell biology at the University of Uppsala.

The US Department of Health and Human Services has appointed Robert Kolodner as head of the Office of the National Coordinator for Health Information Technology. Kolodner has been serving as interim coordinator since September [BioInform 09-29-06].  
Kolodner joined HHS from the Department of Veterans Affairs' Veterans Health Administration, where he was chief health informatics officer. 

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.